MediWound
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 100
- Market Cap
- $186.6M
- Website
- http://www.mediwound.com
- Introduction
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
NexoBrid Shows Superior Results in Phase III Pediatric Burn Treatment Study
• Phase III CIDS trial demonstrates NexoBrid's effectiveness in pediatric burn patients, achieving complete eschar removal in one day compared to six days with standard care.
• The enzymatic treatment significantly reduced the need for surgical intervention, with only 8.3% of NexoBrid-treated patients requiring surgical excision versus 64.4% in standard care.
• Study results published in Burns journal validate NexoBrid's safety profile and long-term outcomes, supporting its recent pediatric use approval in the U.S., E.U., and Japan.
Mediwound Receives Buy Rating Due to EscharEx's Market Potential
Mediwound has been given a Buy rating by Michael Okunewitch of Maxim Group, driven by the promising market potential of its product EscharEx in chronic wound care, with a price target of $30.00.
MediWound Initiates Phase III Trial of EscharEx for Venous Leg Ulcers
• MediWound has commenced a Phase III clinical trial (VALUE) to evaluate EscharEx for the treatment of venous leg ulcers (VLUs).
• The VALUE trial is a randomized, double-blind, placebo-controlled study across 40 sites in the U.S. and Europe, enrolling 216 patients.
• EscharEx has shown promise in Phase II trials, demonstrating effective and rapid debridement of chronic wounds, potentially redefining VLU treatment.
• An interim analysis of the VALUE trial is expected in mid-2026, with strategic collaborations in place to ensure consistent wound management.
MediWound Initiates Phase II Trial of EscharEx for Venous Leg Ulcer Treatment
• MediWound has commenced a Phase II clinical trial to assess EscharEx for treating venous leg ulcers, with results expected to support a BLA submission.
• The trial is a randomized, multicenter study comparing EscharEx to collagenase ointment (Santyl) and placebo across 45 patients in the U.S. and Europe.
• Strategic R&D collaborations with Solventum and Mölnlycke Health Care will ensure consistency in the study through the use of advanced wound care products.
• EscharEx, a bioactive debridement therapy, has shown promise in earlier trials and is also being developed for diabetic foot ulcers.
© Copyright 2025. All Rights Reserved by MedPath